The Mi15 monoclonal antibody (anti-Syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens

Citation
V. Costes et al., The Mi15 monoclonal antibody (anti-Syndecan-1) is a reliable marker for quantifying plasma cells in paraffin-embedded bone marrow biopsy specimens, HUMAN PATH, 30(12), 1999, pp. 1405-1411
Citations number
37
Categorie Soggetti
Research/Laboratory Medicine & Medical Tecnology","Medical Research Diagnosis & Treatment
Journal title
HUMAN PATHOLOGY
ISSN journal
00468177 → ACNP
Volume
30
Issue
12
Year of publication
1999
Pages
1405 - 1411
Database
ISI
SICI code
0046-8177(199912)30:12<1405:TMMA(I>2.0.ZU;2-M
Abstract
Plasmocyte selective monoclonal antibodies (MAb) recognizing syndecan-1 hav e recently been described. They belong to a new cluster, CD138. Using the M Ab MI15, we investigated the expression of syndecan-1 in routinely paraffin -embedded tissues. Nontumoral lymph nodes (25 cases) and bone marrow biopsy specimens (63 cases) showed strong membrane staining of plasma cells only, allowing accurate analysis of the nuclear structure. The MI15 positivity c orrelated with kappa and lambda light chain expression in the cytoplasm. Th e percentages of plasma cells calculated in bone marrow biopsy specimens af ter MI15 staining were, respectively, 2.1% (range, 1% to 4%) in normal bone marrows, 8.5% (range, 5 to 17) in reactive plasmocytosis, and 4.66% in mon oclonal gammapathy of undetermined significance (MGUS) patients (range, 1 t o 13), in the same range but slightly higher than those obtained on smears or on hematoxylin and eosin (H&E)-stained sections. In multiple myeloma (40 cases), all plasma cell types were marked, and Mi15 MAb gave additional in formation in 8 of 40 (20%) patients. In lymph nodes, Mi15 MAb reacted with Reed-Sternberg cells of classical Hodgkin's disease in 23 of 31 cases (74%) with variable intensity. In contrast, nodular lymphocyte predominance Hodg kin's disease (10 cases), most B cell lymphomas (88 of 107 cases) and all T cell lymphomas (30 cases) were negative. In B cell lymphomas, plasmocytoma s (8 cases), plasmocytic lymphomas (2 cases), and 5 of 13 cases of immunobl astic lymphoma with plasmocytoid differentiation were stained. In lymphopla smocytoid lymphomas (4 lymph nodes and 20 bone marrow biopsy specimens), on ly mature plasma cells were positive. Moreover, a wide distribution of synd ecan-1 was observed in normal and tumoral epithelial tissues. Finally, Mi15 MAb appears to be a reliable marker for identifying and quantifying normal and tumoral plasma cells in paraffin-embedded bone marrow and lymph node s amples. Copyright (C) 1999 by W.B. Saunders Company.